Skip to main content
Blizard Institute - Faculty of Medicine and Dentistry


Professor of Haemostasis and Thrombosis

Telephone: 020 359 41869


John Pasi qualified in medicine from University of Birmingham in 1983 and subsequently undertook a PhD in Immunology. Moving to London in 1991 he completing his training in haematology as a Lecturer at the Royal Free Hospital. He was appointed as a consultant, specializing in haemostasis and thrombosis, at the Royal Free in 1993 and then moved to Leicester to take up the foundation Chair in Haematology in 1999. Since 2003 he has been Professor of Haemostasis and Thrombosis at QMUL.

His clinical practice today spans both adults and children and covers all aspects of haemostasis and thrombosis. He had been the Haemophilia Centre Director at Barts Health since 2007.

He has also been involved in the development of national policy and guideline formulation. Previously he was an advisor to the Parliamentary Health Select Committee and worked with the Department of Health on VTE prevention policy.

He is a member of NHS England Clinical Reference Group (GRG) for Inherited Bleeding Disorders, leads the link between the CRG and NIHR on research and co-chair of the ISTH Scientific and Standardization Committee on factor VIII, factor IX and rare coagulation disorders and the WFH Gene Therapy Roundtable.


Research Interests:

John Pasi’s research interests cover many aspects of inherited and acquired bleeding and clotting disorders, particularly new bioengineered therapies for haemophilia, novel therapies for haemophilia including gene therapy and RNAi technologies as well as the optimization of currently available therapies. He is closely involved in the design and development of clinical trials for new therapies and evolving phase 1-4 programmes. Currently he is the lead for a number of multicentre global trials using these new technologies.


Bowles L, Platton S, Yartey N, Dave M, Lee K, Hart DP, MacDonald V, Green L et al.(2020). Lupus Anticoagulant and Abnormal Coagulation Tests in Patients with Covid-19. New England Journal of Medicine 

  1. 1056/NEJMc2013656
  2. 1056/NEJMoa1908490


Pasi KJ, Rangarajan S, Mitchell N, Lester W, Symington E, Madan B, Laffan M, Russell CB et al.(2020). Multiyear follow-up of AAV5-hFVIII-SQ gene therapy for hemophilia A. New England Journal of Medicine vol. 382, (1) 29-40. 


Pasi KJ, Rangarajan S, Georgiev P, Mant T, Creagh MD, Lissitchkov T, Bevan D, Austin S et al.(2017). Targeting of Antithrombin in Hemophilia A or B with RNAi Therapy. New England Journal of Medicine 

  1. 1056/NEJMoa1616569
  2. 1056/NEJMoa1708483


Rangarajan S, Walsh L, Lester W, Perry D, Madan B, Laffan M, Yu H, Vettermann C et al.(2017). AAV5-factor VIII gene transfer in severe hemophilia A. New England Journal of Medicine vol. 377, (26) 2519-2530. 


Powell JS, Pasi KJ, Ragni MV, Ozelo MC, Valentino LA, Mahlangu JN, Josephson NC, Perry D et al.(2013). Phase 3 Study of Recombinant Factor IX Fc Fusion Protein in Hemophilia B. New England Journal of Medicine  vol. 369, (24) 2313-2323. 

  1. 1056/NEJMoa1305074


Professor Pasi's research publications can be found here:

Back to top